Pelthos Therapeutics Inc.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

PTHS$8.90-5.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

FOR THE****THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

	For the Three months Ended September 30,		For the Nine months Ended September 30,
	2025	2024	2025	2024
Revenue
Net product revenues	$7,112	$—	$7,112	$—
License and collaboration revenues	294	—	294	—
Total revenue	7,406	—	7,406	—
Operating expenses
Cost of goods sold	2,316	—	2,316	—
Selling, general and administrative	19,628	1,634	23,984	4,853
Research and development	145	415	854	894
Amortization of intangible assets	679	—	679	—
Total operating expenses	22,768	2,049	27,833	5,747
Operating loss	(15,362)	(2,049)	(20,427)	(5,747)
Other (expense) income
Interest expense	(1,346)	(39)	(1,698)	(678)
Interest income and other income	5	393	5	396
Total other (expense) income	(1,341)	354	(1,693)	(282)
Net loss before provision for income taxes	(16,703)	(1,695)	(22,120)	(6,029)
Provision for income taxes	(465)	—	(465)	—
Net loss and comprehensive loss	$(16,238)	$(1,695)	$(21,655)	$(6,029)
Net loss per common share - basic and diluted	$(5.30)	$(2.93)	$(14.96)	$(11.12)
Weighted average number of common shares outstanding during the period - basic and diluted	3,061,488	579,229	1,447,469	542,036

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.